chronic%20lymphocytic%20leukemia
CHRONIC LYMPHOCYTIC LEUKEMIA

Chronic lymphocytic leukemia (CLL) is a malignant, chronic lymphoproliferative disorder characterized by proliferation and accumulation of monoclonal B-cells in the bone marrow, peripheral blood, lymph nodes, liver and spleen.

It is the most common form of adult leukemia in the Western world but rare in Asians.

Exact etiology is unknown but usually associated with genetic aberrations and lesions.

 

Chronic%20lymphocytic%20leukemia Signs and Symptoms

Introduction

  • The most common form of adult leukemia in the Western world but less common in Asians

Definition

  • A chronic lymphoproliferative disorder characterized by progressive accumulation of monoclonal B-cell lymphocytes found in the blood and bone marrow

Pathophysiology

  • Commonly associated genetic aberrations include:
    • p53 tumor suppressor gene mutation
    • Chromosomal deletions (eg chromosome 17p, chromosome 11q, chromosome 13q)
    • Chromosomal alteration (trisomy 12)

Signs and Symptoms

  • Enlarged lymph nodes
  • Systemic symptoms: Tiredness, fever, night sweats, weight loss
  • Symptoms of anemia or infection

Risk Factors

  • Chemical exposure
  • Family history - 1st degree relatives
  • Race - higher incidence in Caucasians compared to African Americans and Asians
  • Gender - increased incidence in men compared to women
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 09 Oct 2020

Individualized starting dose (ISD) of maintenance niraparib improves progression-free survival (PFS) vs placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), results of the NORA trial have shown.

Dr Margaret Shi, 14 May 2020
Pembrolizumab monotherapy improves overall survival (OS) and cancer control compared with platinum-based chemotherapy in patients with untreated locally advanced or metastatic programmed death-ligand 1 (PD-L1)–positive non-small-cell lung cancer (NSCLC) regardless of STK11 or KEAP1 mutation status, according to results of the phase III KEYNOTE-042 study.